Editorial: Bioengineered Nanoparticles in Cancer Therapy
Payam Zarrintaj
Masoud Mozafari
Henri Vahabi
Tomy J. Gutiérrez
Mohammad Reza Saeb- 1Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States
- 2Department of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
- 3Université de Lorraine, CentraleSupélec, LMOPS, Metz, France
- 4Grupo de Materiales Compuestos Termoplásticos (CoMP), Instituto de Investigaciones en Ciencia y Tecnología de Materiales (INTEMA), Facultad de Ingeniería, Universidad Nacional de Mar del Plata (UNMdP) y Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mar del Plata, Argentina
- 5Department of Resin and Additives, Institute for Color Science and Technology, Tehran, Iran
Editorial on the Research Topic
Cancer is a genetic disease associated with the rapid growth of abnormal cells, which provoked the death of almost 10 million people worldwide during 2020 (WHO, 2021a), placing it among the top 10 causes of death worldwide (WHO, 2021b). In this context, numerous efforts have been made with the aim of preventing, detecting and treating this disease effectively without major side effects in terms of damage to healthy tissues, insulin resistance, Orthostatic hypotension, among others. In particular, engineered nanoparticles are currently playing an important role in this field as controlled release systems for anticancer drugs (Shi et al., 2017; Khodadadi Yazdi et al., 2020), theragnostic devices (Chauhan and Jain, 2013; Gutiérrez and Alvarez, 2018; Gutiérrez, 2018; Wolfram and Ferrari, 2019, among others.
Traditional cancer treatments have shown several limitations. Nonetheless, diverse technologies based on nanotechnology have shown significant advances with the aim of obtaining a more efficient and safe cancer therapy. Despite this, several key obstacles related to the use of nanoparticles for cancer therapy such as the complexity and heterogeneity of tumor biology, a lack of understanding of nano-bio interactions, as well as chemical, manufacturing and control challenges must be further studied for clinical success. This research topic addresses some novel aspects of engineering that take advantage of our growing understanding of bionano behaviors and interactions to develop more efficient nanotherapies for cancer patients. Keeping this in mind, in this research topic, Sanità et al. reviewed the most recent techniques for surface modification and functionalization of nanoparticles in order to improve their biocompatibility and cellular uptake behavior. Similarly, Cheng et al. summarized and analyzed the current research progresses and challenges in tumor microenvironment-responsive shrink-sized drug delivery nanosystems. Cheng et al. also discussed the current implications and knowledge for promoting deep penetration into tumors using nanoparticles. Meanwhile, Chen et al. used two novel HLA-A2-restricted cytotoxic T lymphocyte epitopes (SV95–6 and SV95–7 peptides) derived from survivin (SV, pectic tumor antigen), and were then loaded into human dendritic cell/poly(lactic-co-glycolic) acid-based nanoparticles, thus obtaining advanced materials specific against cancer cells. It should also be noted that Chen et al. carried out major histocompatibility complex peptide binding algorithms to predict a range of modified SV95 decamers (from SV95–2 to SV95–10) based on the natural SV95–104 peptide sequence of ELTLGEFLKL. On the other hand, Sharifiaghdam et al. designed and synthesized new layer-by-layer selenium-based nanocomplexes as carriers of small interfering RNA with improved stability and a dual mode of action against tumors: gene silencing and apoptosis induction in cancer cells. To close this research topic, Shah et al. reported theranostic optical imaging probes based on shortwave infrared (SWIR)-emitting rare earth-doped nanoparticles encapsulated with human serum albumin (ReANCs), which demonstrated superior surveillance ability for detecting micro-lesions at depths of 1 cm in an animal models of breast cancer metastasis, thereby promising an ability for follow-up therapy based on SWIR fluorescence measurements from tumor-targeted ReANCs.
The role of nanotechnology in cancer research has grown dramatically in recent years. However, only a few dozen nano-based technologies have reached the market so far, primarily cell-scale targeted bionanosystems, and controlled and sustained carries of desired biomolecules. To change this, we must reconsider traditional views and rethink how we conduct translational cancer nanomedicine research.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Chauhan, V. P., and Jain, R. K. (2013). Strategies for Advancing Cancer Nanomedicine. Nat. Mater 12, 958–962. doi:10.1038/nmat3792
Gutiérrez, T. J., and Alvarez, V. A. (2018). “Nanoparticles for Hyperthermia Applications,” in Handbook of Nanomaterials for Industrial Applications: Micro and Nano Technologies. Editor C. M. Hussain (EE.UU: Elsevier), 563–576. doi:10.1016/b978-0-12-813351-4.00032-8
Gutiérrez, T. J. (2018). “Biocomposites for Hyperthermia Applications,” in Biocomposites: Biomedical and Environmental Applications. Editors S. Ahmed, S. Ikram, S. Kanchi, and K. Bisetty (Singapore: Pan Stanford Publishing), 97–134. doi:10.1201/9781315110806-4
Khodadadi Yazdi, M., Taghizadeh, A., Taghizadeh, M., Stadler, F. J., Farokhi, M., Mottaghitalab, F., et al. (2020). Agarose-based Biomaterials for Advanced Drug Delivery. J. Controlled Release 326, 523–543. doi:10.1016/j.jconrel.2020.07.028
Shi, J., Kantoff, P. W., Wooster, R., and Farokhzad, O. C. (2017). Cancer Nanomedicine: Progress, Challenges and Opportunities. Nat. Rev. Cancer 17, 20–37. doi:10.1038/nrc.2016.108
Wolfram, J., and Ferrari, M. (2019). Clinical Cancer Nanomedicine. Nano Today 25, 85–98. doi:10.1016/j.nantod.2019.02.005
World Health Organization (WHO (2021a).. International Agency for Research on Cancer. Available at: https://gco.iarc.fr/today/home.. accessed May 05, 2021
World Health Organization (WHO (2021b). The Top 10 Causes of Death. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. accessed May 05, 2021
Keywords: bioengineering, biomaterials, cancer therapy, nanoparticles, nanotechnology
Citation: Zarrintaj P, Mozafari M, Vahabi H, Gutiérrez TJ and Saeb MR (2021) Editorial: Bioengineered Nanoparticles in Cancer Therapy. Front. Mol. Biosci. 8:706277. doi: 10.3389/fmolb.2021.706277
Received: 07 May 2021; Accepted: 30 June 2021;
Published: 13 July 2021.
Edited by:
William C. Cho, Queen Elizabeth Hospital, ChinaReviewed by:
Stephen Lee Rego, Eva Garland Consulting, United StatesCopyright © 2021 Zarrintaj, Mozafari, Vahabi, Gutiérrez and Saeb. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tomy J. Gutiérrez, tomy.gutierrez@fi.mdp.edu.ar
†Present address:Masoud Mozafari, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada